Metraipolis › archive › dc_37b642fcb78e

Harnessing digital health to objectively assess cancer-related fatigue: The impact of fatigue on mobility performance — Europe PMC PMID:33636720

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/33636720
DOI
10.1371/journal.pone.0246101
License (as archived)
CC0-1.0
Archived
2026-11-05T19:32:23.618Z
SHA-256 of the archived text
ef97b084c18ff7d19614e7d03f9d2d992fb754485f259641385b2ec790a0f21b
Stable URL of this page
https://metraipolis.com/documento/dc_37b642fcb78e

How to cite

Harnessing digital health to objectively assess cancer-related fatigue: The impact of fatigue on mobility performance — Europe PMC PMID:33636720 — Europe PMC (en), https://europepmc.org/article/MED/33636720 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_37b642fcb78e (Metraipolis archive dc_37b642fcb78e, sha256 ef97b084c18ff7d19614e7d03f9d2d992fb754485f259641385b2ec790a0f21b)
BibTeX
@misc{dc37b642fcb78e,
  title = {Harnessing digital health to objectively assess cancer-related fatigue: The impact of fatigue on mobility performance — Europe PMC PMID:33636720},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/33636720},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_37b642fcb78e; sha256 ef97b084c18ff7d19614e7d03f9d2d992fb754485f259641385b2ec790a0f21b},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/33636720. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Objective: Cancer-related fatigue (CRF) is highly prevalent among cancer survivors, which may have long-term effects on physical activity and quality of life. CRF is assessed by self-report or clinical observation, which may limit timely diagnosis and management. In this study, we examined the effect of CRF on mobility performance measured by a wearable pendant sensor. Methods: This is a secondary analysis of a clinical trial evaluating the benefit of exercise in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN). CRF status was classified based on a Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score ≤ 33. Among 28 patients (age = 65.7±9.8 years old, BMI = 26.9±4.1kg/m2, sex = 32.9%female) with database variables of interest, twenty-one subjects (75.9%) were classified as non-CRF. Mobility performance, including behavior (sedentary, light, and moderate to vigorous activity (MtV)), postures (sitting, standing, lying, and walking), and locomotion (e.g., steps, postural transitions) were measured using a validated pendant-sensor over 24-hours. Baseline psychosocial, Functional Assessment of Cancer Therapy-General (FACT-G), Falls Efficacy Scale-International (FES-I), and motor-capacity assessments including gait (habitual speed, fast speed, and dual-task speed) and static balance were also performed. Results: Both groups had similar baseline clinical and psychosocial characteristics, except for body-mass index (BMI), FACT-G, FACIT-F, and FES-I (p<0.050). The groups did not differ on motor-capacity. However, the majority of mobility performance parameters were different between groups with large to very large effect size, Cohen's d ranging from 0.91 to 1.59. Among assessed mobility performance, the largest effect sizes were observed for sedentary-behavior (d = 1.59, p = 0.006), light-activity (d = 1.48, p = 0.009), and duration of sitting+lying (d = 1.46, p = 0.016). The largest correlations between mobility performance and FACIT-F were observed for sitting+lying (rho = -0.67, p<0.001) and the number of steps per day (rho = 0.60, p = 0.001). Conclusion: The results of this study suggest that sensor-based mobility performance monitoring could be considered as a potential digital biomarker for CRF assessment. Future studies warrant evaluating utilization of mobility performance to track changes in CRF over time, response to CRF-related interventions, and earlier detection of CRF.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-02-26).
Identificativi: PMID 33636720 · PMCID PMC7910036 · DOI 10.1371/journal.pone.0246101.
Pagina: https://europepmc.org/article/MED/33636720 — https://doi.org/10.1371/journal.pone.0246101. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-05T19:28:59.085Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.